Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559492 · ClinicalTrials.gov registry record · Phase 1
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 142
- Enrollment target
NCT02559492 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 142 participants.
The verdict
NCT02559492, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 142 participants
- Enrollment target
Study Summary
This is an open-label, Phase 1b, platform study in subjects with advanced or metastatic solid tumors. The study will be divided into 3 parts (Part 1a, Part 1b, and Part 2). Part 1a will evaluate a JAK inhibitor with JAK1 selectivity (Itacitinib) in combination with an IDO1 inhibitor (epacadostat; INCB024360; Group A) and Itacitinib in combination with a PI3K-delta inhibitor (INCB050465; Group B) to determine the MTD or PAD and the recommended Part 1b doses for each combination. Once the recommended dose has been identified for each treatment group in Part 1a, subjects with advanced solid tumors will be enrolled into expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b). In Part 2, additional expansion cohorts will be enrolled to further evaluate lower doses of itacitinib and INCB050465 in subjects with select tumor types.
Interventions
- DRUG Epacadostat
- DRUG Itacitinib
- DRUG INCB050465
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2015-11 |
| Est. Completion | 2019-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02559492
The ClinicalTrials.gov registry entry for NCT02559492 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Epacadostat is the first listed.
NCT02559492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02559492 about?
NCT02559492 is a clinical study titled "Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors". This is an open-label, Phase 1b, platform study in subjects with advanced or metastatic solid tumors. The study will be divided into 3 parts (Part 1a, Part 1b, and Part 2). Part 1a will evaluate a JAK inhibitor with JAK1 selectivity (Itacitinib) in combination with an IDO1 inhibitor (epacadostat; IN...
What is the current status of trial NCT02559492?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 142 participants. The study started on 2015-11. Estimated completion is 2019-08-18.
What interventions are being tested in trial NCT02559492?
The interventions under investigation include: Epacadostat (DRUG), Itacitinib (DRUG), INCB050465 (DRUG).
Who is sponsoring clinical trial NCT02559492?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.